GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xeris Biopharma Holdings Inc (NAS:XERS) » Definitions » Gross-Profit-to-Asset %

XERS (Xeris Biopharma Holdings) Gross-Profit-to-Asset % : 62.87% (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Xeris Biopharma Holdings Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Xeris Biopharma Holdings's annualized Gross Profit for the quarter that ended in Dec. 2024 was $202.5 Mil. Xeris Biopharma Holdings's average Total Assets over the quarter that ended in Dec. 2024 was $322.1 Mil. Therefore, Xeris Biopharma Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 62.87%.


Xeris Biopharma Holdings Gross-Profit-to-Asset % Historical Data

The historical data trend for Xeris Biopharma Holdings's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xeris Biopharma Holdings Gross-Profit-to-Asset % Chart

Xeris Biopharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
Get a 7-Day Free Trial Premium Member Only 8.28 15.65 27.00 40.55 51.49

Xeris Biopharma Holdings Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.29 42.07 48.21 49.84 62.87

Competitive Comparison of Xeris Biopharma Holdings's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Xeris Biopharma Holdings's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xeris Biopharma Holdings's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Xeris Biopharma Holdings's Gross-Profit-to-Asset % falls into.


;
;

Xeris Biopharma Holdings Gross-Profit-to-Asset % Calculation

Xeris Biopharma Holdings's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=166.238/( (322.602+323.06)/ 2 )
=166.238/322.831
=51.49 %

Xeris Biopharma Holdings's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=202.484/( (321.104+323.06)/ 2 )
=202.484/322.082
=62.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Xeris Biopharma Holdings Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Xeris Biopharma Holdings Business Description

Traded in Other Exchanges
Address
1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Executives
Beth Hecht officer: See Remarks C/O NEOS THERAPEUTICS, INC., 2940 N. HIGHWAY 360, GRAND PRAIRIE TX 75050
John P. Schmid director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Jeffrey W Sherman director C/O IDM PHARMA, INC., 9 PARKER, SUITE 100, IRVINE CA 92618
Steven Pieper officer: Chief Financial Officer XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Dawn Halkuff director C/O XERIS PHARMACEUTICALS, 180 N. LASALLE ST., STE. 1800, CHICAGO IL 60601
Shannon John Patrick Jr officer: See Remarks DURATA THERAPEUTICS, INC., 89 HEADQUARTERS PLAZA NORTH, 14TH FLOOR, MORRISTOWN NJ 07960
Paul R Edick director, officer: See Remarks C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AMES IA 50010
Ricki Louise Fairley director XERIS BIOPHARMA HOLDINGS, INC., 180 N. LASALLE STREET, SUITE 1600, CHICAGO IL 60601
Steven Prestrelski officer: Chief Scientific Officer C/O XERIS PHARMACEUTICALS, 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Marla Persky director ONE BAXTER PARKWAY, DEERFIELD IL 60015
John Johnson director DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Kenneth Erland Johnson officer: See Remarks C/O XERIS PHARMACEUTICALS, INC., 180 N. LASALLE STREET, SUITE 1800, CHICAGO IL 60601
Garheng Kong director 712 COLLEGE AVENUE, MENLO PARK CA 94025
Barbara-jean Anne Bormann-kennedy director 1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144
Barry M. Deutsch officer: See Remarks OVATION PHARMACEUTICALS, INC. FOUR PARKWAY NORTH, SUITE 200 DEERFIELD IL 60015